Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
300 participants
INTERVENTIONAL
2023-01-30
2025-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intravascular Ultrasound Versus Angiography Guided Drug-coated Balloon Treatment for STEMI Patients:a Prospective, Multicenter, Randomized Controlled Trial
NCT04475978
A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.
NCT03998319
Evaluation of Soluble ST2 in Patients Receiving Primary PCI With ST-elevation Myocardial Infarction
NCT02830217
Stent Thrombosis In Acute Coronary Syndromes
NCT00931502
DCB vs. DES in Young STEMI Patients: The DCB-STEMI Trial
NCT07229248
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental group
Drug-coated Balloon (Lepu Medical Technology (Beijing) Co.,Ltd.)
Drug-eluting balloon
Drug eluting balloon was used in the experimental group
Control group
Drug Eluting Stent(Microport Medical)
Drug-eluting stent
Drug eluting stent was used in the control group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Drug-eluting balloon
Drug eluting balloon was used in the experimental group
Drug-eluting stent
Drug eluting stent was used in the control group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Definitely diagnosed as acute ST segment elevation myocardial infarction according to diagnostic criteria
3. Time of onset ≤ 12h
4. Voluntary signing of informed consent
5. After pretreatment, the culprit vessel participates in stenosis ≤ 30%, no type C (or OCT shows that the dissection involves the middle membrane, and the angle is ≥ 90 degrees) or above, no hematoma, and no obvious thrombus (TIMI thrombus load rating ≤ 2)
Exclusion Criteria
2. Those who are allergic to contrast agents, aspirin tablets and Tigrilol tablets;
3. Active bleeding or recent bleeding history
4. Cardiogenic shock and long-term cardiopulmonary resuscitation;
5. The life span is expected to be less than 12 months
6. Angiography showed left main trunk lesion;
7. Angiography shows patients with in stent restenosis
8. Patients who the investigator thinks may affect the normal progress of the study or cannot cooperate well with the study or may cause obvious risks, such as alcoholics or drug abusers, cancer, serious liver, kidney, lung, endocrine (such as uncontrolled diabetes or thyroid disease), nervous or blood system diseases;
9. Known or suspected pregnancy (baseline ß - hCG pregnancy test must be conducted for women in childbearing period), women in menstrual period.
10. The criminal blood vessel has C-type or above dissection after pretreatment, and there is coronary hematoma.
11. After pretreatment, criminal vessels still have obvious thrombus residues (TIMI thrombus load grade ≥ 3)
12. OCT confirms that the criminal lesion is caused by plaque erosion
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Henan Institute of Cardiovascular Epidemiology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fuwai Central China Cardiovascular Hospital
Zhengzhou, Henan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HenanICE202208
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.